FDA Grants 510(k) Clearance for Sonic Incytes’ Velacur ONE™, AI-guided point of care ultrasound for the management of chronic liver diseases
VANCOUVER, British Columbia–(BUSINESS WIRE)–Sonic Incytes Medical Corp, proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Velacur ONE™, its point-of-care ultrasound elastography device. Building on the success of its original model, Velacur™, Velacur ONE™ introduces an enhanced interface and features for improved portability and user experience. These improvements enable […]
FDA Grants 510(k) Clearance to Sonic Incytes’ Velacur® Determined Fat Fraction (VDFF), a breakthrough for patients with MASLD and MASH
VANCOUVER, British Columbia — (BUSINESS WIRE) — Sonic Incytes Medical Corp, a leader in point-of-care ultrasound, proudly announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Velacur® Determined Fat Fraction (VDFF). This innovative measurement tool is integrated into the Velacur® device software, combining quantitative measures of ultrasound attenuation and […]
Sonic Incytes Recognized at 2023 LSBC Awards Gala
Sonic Incytes was recognized as a “Company to Watch” at the 25th Annual LSBC Awards Gala, presented by Farris. This recognition underscores Sonic Incytes’ commitment to healthcare innovation and its groundbreaking product, Velacur, which is contributing to the fight against the global epidemic of non-alcoholic fatty liver disease—a condition that impacts nearly 30% of the […]
Sonic Incytes Announces New Non-Dilutive Funding to Enhance Company’s Velacur™️ Medical Device
Sonic Incytes Medical Corp. is pleased to announce its project was selected for investment by the inaugural INOVAIT Focus Fund. INOVAIT is a pan-Canadian network funded by the Government of Canada that invests strategically in projects at the intersection of advanced imaging, minimally-invasive therapies, and artificial intelligence (AI). Through this three-year, non-repayable investment, the Company […]
Sonic Incytes Successfully Completes Series A Raise of US$7.3M to Accelerate VelacurTM Commercialization
Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergies as the lead investor, and support from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels and INP Capital, as well as notable angel investors. […]
Sonic Incytes Selected to Pitch at Innovative HealthTech Competition
Sonic Incytes Medical Corp. has been selected as one of three finalists at the ADA’s 2021 Silicon Valley Leaders Forum HealthTech Showcase, taking place November 19, 2021 in San Mateo, California. Sponsored by Wilson Sonsini, this year’s event will focus on how health technology equity is enabling care for people living with vulnerable conditions. During […]
Sonic Incytes to Present at the Venture Summit Virtual Connect
Sonic Incytes Medical Corp., the developer of VelacurTM, has been selected to present its innovative technology at the upcoming Venture Summit Virtual Connect conference, hosted by youngStartup Ventures from July 6-8, 2021. Sonic Incytes is among the top innovators from the technology, cleantech, life sciences, healthcare and fintech sectors chosen to present to an exclusive […]
Sonic Incytes Selected for RESI Innovator’s Pitch Challenge
Sonic Incytes Medical Corp., the developer of VelacurTM, has been selected to participate in the Innovator’s Pitch Challenge at the upcoming Redefining Early Stage Investments (RESI) conference, held digitally June 8-10, 2021. The Innovator’s Pitch Challenge is an opportunity for early-stage companies to gain additional exposure to conference attendees and pitch directly to a panel […]
Sonic Incytes Takes the Stage at LSI Emerging Medtech Summit
Sonic Incytes Medical Corp., the developers of VelacurTM, will take the stage at the LSI 2021 Emerging Medtech Summit to present its breakthrough solution for addressing fatty liver disease, an urgent, global health crisis exacerbated by the COVID-19 pandemic. Held May 11-13 in California, this premier event connects start-ups that have developed the most innovative […]
Sonic Incytes Selected for MedTech Innovator US 2021 Road Tour
Identified as best-in-class, Sonic Incytes Medical Corp. has been selected to pitch in the virtual MedTech Innovator US 2021 Road Tour on April 14, 2021. Every year, MedTech Innovator selects the best and brightest medtech start-ups that are seeking to improve patient lives through innovation. Sonic Incytes was selected to pitch among the more than 1000 […]